Terry Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10607157/publications.pdf

Version: 2024-02-01

116 papers	10,564 citations	39113 52 h-index	37326 100 g-index
116 all docs	116 docs citations	116 times ranked	7934 citing authors

#	Article	IF	Citations
1	Total-Body Quantitative Parametric Imaging of Early Kinetics of ¹⁸F-FDG. Journal of Nuclear Medicine, 2021, 62, 738-744.	2.8	50
2	Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View. Journal of Nuclear Medicine, 2021, 62, 861-870.	2.8	178
3	Total-Body PET Imaging in Infectious Diseases. PET Clinics, 2021, 16, 89-97.	1.5	9
4	Quantitative PET in the 2020s: a roadmap. Physics in Medicine and Biology, 2021, 66, 06RM01.	1.6	36
5	Quantitative accuracy in total-body imaging using the uEXPLORER PET/CT scanner. Physics in Medicine and Biology, 2021, 66, 205008.	1.6	21
6	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage. JAMA Neurology, 2021, 78, 1179.	4.5	25
7	Total Body PET Imaging From Mice to Humans. Frontiers in Physics, 2020, 8, .	1.0	7
8	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet, The, 2019, 393, 2613-2623.	6.3	134
9	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology, The, 2019, 18, 643-652.	4.9	68
10	First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*. Journal of Nuclear Medicine, 2019, 60, 299-303.	2.8	453
11	The Effects of Delay on the Input Function for Early Dynamics in Total Body Parametric Imaging. , 2019, , .		2
12	Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. Journal of Nuclear Medicine, 2018, 59, 3-12.	2.8	474
13	History and future technical innovation in positron emission tomography. Journal of Medical Imaging, 2017, 4, 011013.	0.8	165
14	Total-body imaging: Transforming the role of positron emission tomography. Science Translational Medicine, 2017, 9, .	5.8	175
15	Optimizing I/O forwarding techniques for extreme-scale event tracing. Cluster Computing, 2014, 17, 1-18.	3.5	11
16	Ultra Staging to Unmask the Prescribing of Adjuvant Therapy in Cancer Patients: The Future Opportunity to Image Micrometastases Using Total-Body ¹⁸F-FDG PET Scanning. Journal of Nuclear Medicine, 2014, 55, 696-697.	2.8	19
17	The Potential for Low-Dose Functional Studies in Maternalâ€“Fetal Medicine Using PET/MR Imaging. Journal of Nuclear Medicine, 2013, 54, 2016-2017.	2.8	12
18	Enabling event tracing at leadership-class scale through I/O forwarding middleware. , 2012, , .		14

#	Article	IF	Citations
19	Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncology, The, 2012, 13, e116-e125.	5.1	34
20	Oxygen metabolism, oxygen extraction and positron emission tomography: Historical perspective and impact on basic and clinical neuroscience. NeuroImage, 2012, 61, 492-504.	2.1	62
21	The Development, Past Achievements, and Future Directions of Brain PET. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1426-1454.	2.4	119
22	Realizing the Full Potential of PET for Measuring the Biodistribution of Novel Anticancer Agents. Journal of Nuclear Medicine, 2011, 52, 1500-1500.	2.8	3
23	Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. Theranostics, 2011, 1, 290-301.	4.6	14
24	Bias in iterative reconstruction of low-statistics PET data: Benefits of a resolution model. , 2009, , .		3
25	Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. Molecular Cancer Therapeutics, 2009, 8, 303-309.	1.9	22
26	Maximizing model parameter precision by optimizing dose in 3D [¹⁵O]H<inf>2</inf>O PET scans. , 2008, , .		0
27	HPC-Colony. Operating Systems Review (ACM), 2006, 40, 43-49.	1.5	4
28	Carbogen and Nicotinamide Increase Blood Flow and 5-Fluorouracil Delivery but not 5-Fluorouracil Retention in Colorectal Cancer Metastases in Patients. Clinical Cancer Research, 2006, 12, 3115-3123.	3.2	35
29	2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans. Clinical Cancer Research, 2005, 11, 4341-4347.	3.2	19
30	The enabling technologies needed for PET-based molecular imaging to support drug development. Drug Discovery Today: Technologies, 2005, 2, 305-309.	4.0	4
31	The potential of positron-emission tomography to study anticancer-drug resistance. Nature Reviews Cancer, 2004, 4, 457-469.	12.8	35
32	Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11 C]diprenorphine binding and PET. European Journal of Pain, 2004, 8, 479-485.	1.4	135
33	Knocking out radiotracers for molecular imaging with PET. Drug Discovery Today, 2003, 8, 734-735.	3.2	3
34	Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate. Journal of Clinical Oncology, 2003, 21, 2823-2830.	0.8	215
35	Techniques for imaging neuroscience. British Medical Bulletin, 2003, 65, 3-20.	2.7	47
36	Improving the Scalability of Parallel Jobs by adding Parallel Awareness to the Operating System. , 2003, , .		72

#	Article	IF	Citations
37	Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Research, 2003, 63, 2409-15.	0.4	72
38	Molecular imaging: what picture does it paint for future oncology?. Drug Discovery Today, 2002, 7, 741-743.	3.2	5
39	Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Research, 2002, 62, 5698-702.	0.4	60
40	In-vivo measurement of activated microglia in dementia. Lancet, The, 2001, 358, 461-467.	6.3	983
41	Pharmacokinetic Evaluation of N-[2-(Dimethylamino)Ethyl]Acridine-4-Carboxamide in Patients by Positron Emission Tomography. Journal of Clinical Oncology, 2001, 19, 1421-1429.	0.8	76
42	Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. NeuroReport, 2001, 12, 3439-3442.	0.6	108
43	Dipyridamole-induced increased glucose uptake in patients with single-vessel coronary artery disease assessed with PET. Journal of Nuclear Cardiology, 2001, 8, 339-346.	1.4	30
44	In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discovery Today, 2001, 6, 293-302.	3.2	93
45	Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet, The, 2000, 355, 2125-2131.	6.3	78
46	Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With N-Phosphonacetyl-l-aspartate, Folinic Acid, and Interferon Alfa. Journal of Clinical Oncology, 1999, 17, 1580-1580.	0.8	49
47	Present and future capabilities of molecular imaging techniques to understand brain function. Journal of Psychopharmacology, 1999, 13, 324-329.	2.0	9
48	Radio-imaging in small animals. Journal of Psychopharmacology, 1999, 13, 352-357.	2.0	22
49	An automated radiosynthesis of 2-[]thymidine using anhydrous []urea derived from []phosgene. Applied Radiation and Isotopes, 1999, 51, 377-388.	0.7	32
50	Measurement of Changes in Opioid Receptor Binding in Vivo During Trigeminal Neuralgic Pain Using [11C]Diprenorphine and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 803-808.	2.4	99
51	Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 173-176.	3.3	198
52	Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study. Cancer Chemotherapy and Pharmacology, 1998, 42, 183-193.	1.1	57
53	Positron emission tomography (pet) methodology for small animals and its application in radiopharmaceutical preclinical investigation. Nuclear Medicine and Biology, 1998, 25, 729-732.	0.3	40
54	Decreased Brain GABAA-Benzodiazepine Receptor Binding in Panic Disorder. Archives of General Psychiatry, 1998, 55, 715.	13.8	344

#	Article	IF	Citations
55	Experience with fully 3D PET and implications for future high-resolution 3D tomographs. Physics in Medicine and Biology, 1998, 43, 777-786.	1.6	29
56	Parametric image reconstruction using spectral analysis of PET projection data. Physics in Medicine and Biology, 1998, 43, 651-666.	1.6	85
57	Classification of Dynamic PET Images Using a Priori Kinetic Factors. , 1998, , 107-115.		5
58	New Opportunities in Molecular Imaging Using Pet. Drug Information Journal, 1997, 31, 991-995.	0.5	8
59	A method for calibrating three-dimensional positron emission tomography without scatter correction. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 660-664.	2.2	16
60	ECAT ART â€" a continuously rotating PET camera: Performance characteristics, initial clinical studies, and installation considerations in a nuclear medicine department. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 6-15.	2.2	80
61	Enhanced Myocardial 18F-2-Fluoro-2-Deoxyglucose Uptake After Orthotopic Heart Transplantation Assessed by Positron Emission Tomography. Journal of the American College of Cardiology, 1997, 30, 533-538.	1.2	27
62	Analysis of Dynamic Radioligand Displacement or â€œActivationâ€•Studies. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 80-93.	2.4	27
63	Effect of long-term Î²2-agonist dosing on human cardiac Î²-adrenoceptor expression in vivo: Comparison with changes in lung and mononuclear leukocyte Î²-receptors1. Journal of Nuclear Cardiology, 1997, 4, 532-538.	1.4	22
64	Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Applied Radiation and Isotopes, 1997, 48, 487-492.	0.7	9
65	The imaging science of positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 807-813.	2.2	77
66	The role of positron emission tomography within the spectrum of medical imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 207-211.	2.2	100
67	A Cluster Analysis Approach for the Characterization of Dynamic PET Data. , 1996, , 301-306.		49
68	Development of an On-Line Blood Detector System for PET Studies in Small Animals. , 1996, , 62-66.		9
69	Noninvasive Quantification of Regional Myocardial Metabolic Rate for Oxygen by Use of ¹⁵ O ₂ Inhalation and Positron Emission Tomography. Circulation, 1996, 94, 792-807.	1.6	69
70	Trends in Instrumentation. Developments in Cardiovascular Medicine, 1996, , 3-47.	0.1	0
71	Assessment of Myocardial Viability Using 15O-Water. Developments in Cardiovascular Medicine, 1996, , 241-262.	0.1	0
72	Performance comparison of a state-of-the-art neuro-SPET scanner and a dedicated neuro-PET scanner. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 381-7.	2.2	22

#	Article	IF	Citations
73	Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 297.	2.2	0
74	Dosimetry of intravenously administered oxygen-15 labelled water in man: a model based on experimental human data from 21 subjects. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 1126-34.	2.2	33
75	Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 297-305.	2.2	213
76	Quantitation of [11C]diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols. Journal of Neuroscience Methods, 1994, 51, 123-134.	1.3	47
77	Imaging Transient, Randomly Occurring Neuropsychological Events in Single Subjects with Positron Emission Tomography: An Event-Related Count Rate Correlational Analysis. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 771-782.	2.4	41
78	Spectral Analysis of Dynamic PET Studies. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 15-23.	2.4	452
79	Detection of Thirty-Second Cognitive Activations in Single Subjects with Positron Emission Tomography: A New Low-Dose H₂¹⁵O Regional Cerebral Blood Flow Three-Dimensional Imaging Technique. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 617-629.	2.4	227
80	Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: A study with positron emission tomography. Journal of the American College of Cardiology, 1993, 22, 1653-1660.	1.2	91
81	Dipyridamole vasodilator response after human orthotopic heart transplantation: Quantification by oxygen-15-labeled water and positron emission tomography. Journal of the American College of Cardiology, 1992, 19, 100-106.	1.2	46
82	Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state technique: effect of tissue heterogeneity. British Journal of Radiology, 1992, 65, 697-700.	1.0	31
83	Dynamic monitoring of [11C]diprenorphine in rat brain using a prototype positron imaging device. Journal of Neuroscience Methods, 1991, 40, 223-232.	1.3	13
84	A method for measuring the absolute sensitivity of positron emission tomographic scanners. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 374-379.	2.2	105
85	A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [¹¹C]Nomifensine Uptake Using Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 307-316.	2.4	73
86	Quality control procedures in positron tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1989, 15, 736-740.	2.2	18
87	Aspects of three dimensional reconstruction for a multi ring positron tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1989, 15, 741-745.	2.2	19
88	The C¹⁵O₂ Build-up Technique to Measure Regional Cerebral Blood Flow and Volume of Distribution of Water. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 461-470.	2.4	59
89	Increased Regional Myocardial Glucose Utilisation in Patients with Chronic Stable Angina as Assessed by Positron Emission Tomography (PET). Clinical Science, 1989, 76, 55P-55P.	0.0	0
90	Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers. Journal of Neuroscience Methods, 1988, 23, 121-129.	1.3	89

#	Article	IF	Citations
91	Abnormalities in myocardial metabolism in patients with unstable angina as assessed by positron emission tomography. Cardiovascular Drugs and Therapy, 1988, 2, 41-46.	1.3	35
92	Stability of Arterial Concentrations during Continuous Inhalation of C15O2 and 15O2 and the Effects on Computed Values of CBF and CMRO2. Journal of Cerebral Blood Flow and Metabolism, 1988, 8, 411-417.	2.4	8
93	Glucose utilizationin vivo by human pulmonary neoplasms. Cancer, 1987, 60, 2682-2689.	2.0	234
94	Measurement of Glucose Utilisation with [18F]2-Fluoro-2-Deoxy-D-Glucose: A Comparison of Different Analytical Methods. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 161-172.	2.4	76
95	Correction for Intravascular Activity in the Oxygen-15 Steady-State Technique is Independent of the Regional Hematocrit. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 372-374.	2.4	31
96	Positron Emission Tomography in Oncology. , 1987, , 191-205.		0
97	Myocardial blood flow and glucose metabolism in exercise induced and spontaneous ischemia. European Journal of Nuclear Medicine and Molecular Imaging, 1986, 12, S49-S50.	2.2	4
98	Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. British Journal of Radiology, 1985, 58, 725-734.	1.0	77
99	Measurement of Cerebral Blood Flow Using Bolus Inhalation of C¹⁵O₂ and Positron Emission Tomography: Description of the Method and its Comparison with the C¹⁵O₂ Continuous Inhalation Method. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 224-234.	2.4	76
100	In vivo Measurement of Regional Cerebral Haematocrit Using Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 317-322.	2.4	145
101	Measurement of Regional Cerebral pH in Human Subjects Using Continuous Inhalation of 11CO2 and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 458-465.	2.4	58
102	A Method to Quantitate the Fractional Extraction of Rubidium-82 across the Bloodâ€"Brain Barrier Using Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 523-534.	2.4	32
103	Quantitative Measurement of Bloodâ€"Brain Barrier Permeability Using Rubidium-82 and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 535-545.	2.4	86
104	Positron emission tomographic studies in aging and cerebrovascular disease at hammersmith hospital. Annals of Neurology, 1984, 15, 112-118.	2.8	32
105	POSITRON EMISSION TOMOGRAPHY FOR IN-VIVO MEASUREMENT OF REGIONAL BLOOD FLOW, OXYGEN UTILISATION, AND BLOOD VOLUME IN PATIENTS WITH BREAST CARCINOMA. Lancet, The, 1984, 323, 131-134.	6.3	165
106	Regional Cerebral Blood Flow and Oxygen Utilization in Edema Associated with Cerebral Tumors. , 1984, , 331-344.		10
107	Correction for the Presence of Intravascular Oxygen-15 in the Steady-State Technique for Measuring Regional Oxygen Extraction Ratio in the Brain: 1. Description of the Method. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 416-424.	2.4	297
108	Correction for the Presence of Intravascular Oxygen-15 in the Steady-State Technique for Measuring Regional Oxygen Extraction Ratio in the Brain: 2. Results in Normal Subjects and Brain Tumour and Stroke Patients. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 425-431.	2.4	122

#	Article	IF	Citations
109	In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Annals of Neurology, 1983, 14, 614-626.	2.8	197
110	Disturbance of oxidative metabolism of glucose in recent human cerebral infarcts. Annals of Neurology, 1983, 14, 627-637.	2.8	114
111	A Statistical Study of the Steady State Technique for Measuring Regional Cerebral Blood Flow and Oxygen Utilisation Using 15O. Journal of Computer Assisted Tomography, 1982, 6, 566-573.	0.5	59
112	Measurement of CBF and CMRO2 using the continuous inhalation of C15O2 and 15O2. Journal of the Neurological Sciences, 1981, 50, 381-389.	0.3	57
113	A Theoretical Study of the Steady-State Model for Measuring Regional Cerebral Blood Flow and Oxygen Utilisation Using Oxygen-15. Journal of Computer Assisted Tomography, 1981, 5, 544-550.	0.5	133
114	Quantitative Measurement of Regional Extravascular Lung Density Using Positron Emission and Transmission Tomography. Journal of Computer Assisted Tomography, 1981, 5, 783-791.	0.5	102
115	POSITRON EMISSION TOMOGRAPHY AND MEASUREMENTS OF REGIONAL TISSUE FUNCTION IN MAN. British Medical Bulletin, 1980, 36, 231-236.	2.7	16
116	Quantitative Measurement of Regional Cerebral Blood Flow and Oxygen Metabolism in Man Using 15O and Positron Emission Tomography. Journal of Computer Assisted Tomography, 1980, 4, 727-736.	0.5	1,173